Rotator Cuff Treatment Market Size

Rotator Cuff Treatment Market Analysis

The Rotator Cuff Treatment Market size is estimated at USD 532.94 million in 2024, and is expected to reach USD 676.95 million by 2029, growing at a CAGR of 4.90% during the forecast period (2024-2029).

The major factors driving the growth of the market are the rising number of sports-related injuries and technological advancements in rotator cuff rupture devices, as well as growing public-private funding grants and educational awareness initiatives. For instance, as per the Australian Institutes of Health and Welfare, in March 2023, 52,300 sports-related injuries in Australia resulted in hospital stays yearly. Arm or shoulder fractures were the most frequent (representing 41% of all fractures, or 10,800 cases). Thus, the growing burden of shoulder and sports injuries will increase the demand for rotator cuff treatment products during the forecast period.

Further, the rotator cuff is a common shoulder injury in athletes. The increasing burden of rotator cuff is expected to contribute to market growth during the forecast period. For instance, according to the article published by the American Academy of Orthopaedic Surgeons (AAOS) in August 2022, almost 2 million people in the United States visit a healthcare provider with issues related to their rotator cuff every year. Thus, the market is expected to gain traction due to the global increase in shoulder and rotator cuff injuries.

The advancement in rotator cuff rupture devices and regulatory approval may increase their effectiveness, likely boosting market growth. For instance, in July 2023, iSmith+Nephew announced the launch of its REGENETEN Bioinductive Implant in India. With more than 100,000 procedures completed globally since its introduction, the REGENETEN implant has significantly impacted how surgeons approach rotator cuff procedures. Thus, the launch of such implants for treating rotator cuff injuries is expected to increase access to patients and physicians during the forecast period.

Additionally, in May 2022, Embody Inc. stated that the Food and Drug Administration (FDA) granted 510(k) clearance for its TAPESTRY RC System to treat rotator cuff dysfunction. The TAPESTRY RC System, which is specifically created for arthroscopic surgeries, combines the healing benefits of the bio-integrative collagen TAPESTRY implant with simplified distribution and bioabsorbable anchor anchoring. As the number of new products receiving FDA approval and hitting the market increases, this trend is expected to impact the industry's growth over the forecast period positively.

Thus, all the aforementioned factors, such as the growing burden of shoulder injuries, technological advancements, and rising approval by the FDA, are expected to boost the market growth. However, the high cost associated with the treatment is expected to hinder market growth during the forecast period.